Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment.
Fiche publication
Date publication
janvier 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric, Dr LIOURE Bruno
Tous les auteurs :
Daguindau E, Lioure B, Buzyn A, Robin M, Faucher C, Kuentz M, Tiberghien P, Deconinck E
Lien Pubmed
Résumé
Remissions of haematological malignancies have been reported after allo-SCT, despite donor cell rejection, suggesting that sustained allogeneic engraftment is not mandatory to obtain a lasting anti-tumour effect. To evaluate the potential benefit from transient post-allo-SCT alloreactivity, we took advantage of the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC) registry to colligate 14 patients with an efficient and long-lasting allogeneic (GVL) effect after allo-SCT for haematological malignancies, despite transient or absent engraftment. None received a second allogeneic graft after autologous recovery. The median duration of remission after autologous reconstitution was 118 (12-252) months. Although we cannot exclude the possibility that some patients were cured before allo-SCT, this retrospective analysis does strongly suggest that an efficient GVL effect can be observed without sustained donor engraftment, and that the transient presence of donor T cells might be sufficient to induce a powerful GVL effect.
Référence
Bone Marrow Transplant. 2010 Jan;45(1):177-80